Health Technology Assessment: Global Advocacy and Local Realities Comment on "Priority Setting for Universal Health Coverage: We Need Evidence-Informed Deliberative Processes, Not Just More Evidence on Cost-Effectiveness"

Int J Health Policy Manag. 2017 Apr 1;6(4):233-236. doi: 10.15171/ijhpm.2016.118.

Abstract

Cost-effectiveness analysis (CEA) can help countries attain and sustain universal health coverage (UHC), as long as it is context-specific and considered within deliberative processes at the country level. Institutionalising robust deliberative processes requires significant time and resources, however, and countries often begin by demanding evidence (including local CEA evidence as well as evidence about local values), whilst striving to strengthen the governance structures and technical capacities with which to generate, consider and act on such evidence. In low- and middle-income countries (LMICs), such capacities could be developed initially around a small technical unit in the health ministry or health insurer. The role of networks, development partners, and global norm setting organisations is crucial in supporting the necessary capacities.

Keywords: Cost-Effectiveness Analysis (CEA); Deliberation; Efficiency; Governance; Universal Coverage.

Publication types

  • Comment

MeSH terms

  • Biomedical Technology
  • Cost-Benefit Analysis
  • Delivery of Health Care*
  • Health Resources
  • Humans
  • Universal Health Insurance*